Identifying biomarkers for lung transplant dysfunction

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to identify diagnostic and prognostic biomarkers associated with lung transplant dysfunction, which is a significant cause of morbidity and mortality in lung transplant recipients. By collecting biological samples from patients undergoing lung transplantation or being followed post-transplant at Foch Hospital, the study will analyze the underlying mechanisms of transplant rejection and failure. The research focuses on understanding the pathophysiological processes through transcriptomics, gene polymorphisms, and cell phenotyping, which will be contextualized with clinical data. This comprehensive approach seeks to improve early diagnosis and management of lung transplant complications.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men or women over 15 years of age
* Suffering from a lung condition requiring a transplant planned at Foch Hospital or being followed up at Foch Hospital following a lung transplant
* Have signed the informed consent form and for patients aged 15 to 18 years that the person(s) exercising parental authority has/have signed the informed consent.
* Be affiliated with a Health Insurance plan.

Exclusion Criteria:

* Pregnant, parturient and/or lactating woman
* Hemoglobin level less than or equal to 8g/dl
* Persons of full age who are subject to a legal protection measure or who are unable to express their consent
* Persons under the protection of justice
* Not being able to follow the study requirements for geographical, social or psychological reasons
* Patient refusal.

Where it's running

• Roux
  Suresnes, France Recruiting

Study contacts

• Study coordinator: Antoine ROUX, Dr
• Email: a.roux@hopital-foch.com
• Phone: 0146252635

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Research on improving outcomes for lung transplant donors and recipients

  This study is trying to see how different donor and medical practices affect the health of lung transplant patients and donors, while also looking for blood markers that might predict complications after the surgery.

  Recruiting at 19 sites Duke University · Los Angeles, California and 18 other locations · NCT06399302

• Cytokine filtration in lung transplantation

  This study is testing whether using a special device to filter out harmful substances during lung transplants can help patients have fewer complications and live longer.

  Recruiting Lund University Hospital · Lund, Skåne County · NCT05526950

• Multidisciplinary non-drug program to improve quality of life after solid organ transplant

  A multidisciplinary, non-drug program using acupuncture, remote physical rehab, and brain-health activities is being tested to see if it can improve quality of life for adults at least one year after heart, kidney, liver, or lung transplant.

  Recruiting The Mediterranean Institute for Transplantation and Advanced Specialized Therapies · Palermo, Palermo · NCT07870811

• Multimodal prospective approach to understand acute and chronic lung transplant rejection

  This project will see if blood tests, airway sampling, imaging, and genetic analyses can identify which adults who have had or are being evaluated for a lung transplant will develop antibody‑mediated rejection and later chronic graft dysfunction.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07516379

• Biomarkers for Response to ECP in Lung Transplant Patients with CLAD

  This study tests early biomarkers from blood and MRI to see if extracorporeal photopheresis helps lung transplant patients with chronic lung allograft dysfunction.

  Recruiting at 2 sites Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT07434869

• Hyperpolarized xenon-129 MRI signatures to detect and manage acute cellular rejection after lung transplant

  We will see if hyperpolarized xenon-129 MRI can detect early acute cellular rejection in recent lung transplant recipients and guide targeted bronchoscopic sampling.

  Recruiting Phase 2 University of Virginia · Charlottesville, Virginia · NCT07046910

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.